Sotera Health (NASDAQ:SHC) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Sotera Health (NASDAQ:SHC) have received a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $15.70.

Several research analysts have recently weighed in on SHC shares. Barclays boosted their price target on shares of Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Royal Bank of Canada reiterated an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a report on Tuesday, August 6th.

Sotera Health Trading Down 0.3 %

Shares of SHC stock opened at $15.46 on Friday. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.44. The firm has a market capitalization of $4.38 billion, a P/E ratio of 110.43 and a beta of 2.07. The stock’s fifty day moving average is $15.86 and its two-hundred day moving average is $13.37. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93.

Sotera Health (NASDAQ:SHC) last released its earnings results on Monday, August 5th. The company reported $0.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.15 by $0.04. The business had revenue of $277.00 million for the quarter, compared to analyst estimates of $266.45 million. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. The business’s revenue was up 8.6% on a year-over-year basis. During the same period last year, the company posted $0.19 EPS. Research analysts expect that Sotera Health will post 0.64 earnings per share for the current fiscal year.

Insider Activity at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the firm’s stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the completion of the transaction, the director now directly owns 49,215,301 shares in the company, valued at $739,705,974.03. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 55.12% of the company’s stock.

Hedge Funds Weigh In On Sotera Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC raised its holdings in Sotera Health by 43.6% in the first quarter. Janus Henderson Group PLC now owns 14,892,868 shares of the company’s stock valued at $178,865,000 after acquiring an additional 4,525,056 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Sotera Health by 27.0% in the 1st quarter. Vanguard Group Inc. now owns 12,145,110 shares of the company’s stock valued at $145,863,000 after purchasing an additional 2,579,248 shares in the last quarter. Sessa Capital IM L.P. grew its stake in shares of Sotera Health by 7.5% during the second quarter. Sessa Capital IM L.P. now owns 4,300,597 shares of the company’s stock worth $51,048,000 after purchasing an additional 300,597 shares in the last quarter. Darsana Capital Partners LP purchased a new position in Sotera Health in the second quarter valued at $29,074,000. Finally, Untitled Investments LP raised its stake in Sotera Health by 47.0% in the first quarter. Untitled Investments LP now owns 1,409,091 shares of the company’s stock valued at $16,923,000 after buying an additional 450,496 shares in the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.